Vanda Pharmaceuticals (VNDA) EBT (2010 - 2026)
Vanda Pharmaceuticals (VNDA) posted EBT of -$48.4 million for Q1 2026, down 27.42% sequentially from -$38.0 million in Q4 2025, and down 29.59% YoY from -$68.8 million in Q1 2025.
Vanda Pharmaceuticals (VNDA) EBT (2010 - 2026) Analysis & Trends
Vanda Pharmaceuticals has reported EBT for 17 years, with the latest figure at -$48.4 million in Q1 2026.
- Quarterly EBT fell 29.59% year-over-year to -$48.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$149.7 million (down 169.13% YoY) and the FY2025 annual result came in at -$138.6 million, down 504.89% from the prior year.
- EBT eased to -$48.4 million in Q1 2026 per VNDA's latest filing, from -$38.0 million in the prior quarter.
- Over five years, EBT peaked at $9.6 million in Q4 2022 and troughed at -$48.4 million in Q1 2026.
- A 5-year average of -$11.3 million and a median of -$5.5 million in 2024 frame the typical range for EBT.
- The sharpest annual moves came in 2023 and 2024: EBT surged 173.08% in 2023, then tumbled 5103.33% in 2024.
- Over 5 years, EBT stood at $9.6 million in 2022, then plunged by 117.28% to -$1.7 million in 2023, then tumbled by 291.15% to -$6.5 million in 2024, then tumbled by 484.92% to -$38.0 million in 2025, then fell by 27.42% to -$48.4 million in 2026.
- According to Business Quant data, EBT over the past three periods registered -$48.4 million, -$38.0 million, and -$28.4 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.39 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.53 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 541.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -644.37 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 312.46 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -2,828.29 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 81.49 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 177.81 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -11.37 Mn |
| 10 | Vanda Pharmaceuticals | 315.57 Mn | 145.54 Mn | 46.97 Mn | -62.38 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -62.38 Mn |
| Mar 31, 2026 | -48.42 Mn |
| Dec 31, 2025 | -38.00 Mn |
| Sep 30, 2025 | -28.39 Mn |
| Jun 30, 2025 | -34.89 Mn |
| Mar 31, 2025 | -37.37 Mn |
| Dec 31, 2024 | -6.50 Mn |
| Sep 30, 2024 | -6.24 Mn |
| Jun 30, 2024 | -5.52 Mn |
| Mar 31, 2024 | -4.66 Mn |
| Dec 31, 2023 | -1.66 Mn |
| Sep 30, 2023 | -120,000.00 |
| Jun 30, 2023 | 2.59 Mn |
| Mar 31, 2023 | 5.53 Mn |
| Dec 31, 2022 | 9.61 Mn |
| Sep 30, 2022 | 5.46 Mn |
| Jun 30, 2022 | 3.79 Mn |
| Mar 31, 2022 | -7.56 Mn |
| Dec 31, 2021 | 8.61 Mn |
| Sep 30, 2021 | 10.72 Mn |